Skip to main content
. Author manuscript; available in PMC: 2012 Oct 5.
Published in final edited form as: Cancer Res. 2011 May 6;71(13):4675–4685. doi: 10.1158/0008-5472.CAN-10-4558

Figure 6. EGFP+ cells after tamoxifen injection in PlpCre+ animals.

Figure 6

(A) Graph (left) indicates percentages of EGFP+/DAPI+ cells in sciatic nerve and DRG/satellite cells and (right) the percent of EGFP+ recombined cells that double labeled with S100β, GFAP, p75, or GS. (B) Double immunolabeling (40×) shows EGFP+/S100β+ cells within the DRG or Sciatic Nerve one day post Tamoxifen. (C) EGFP+/GFAP+ cells are present in the DRG but not Sciatic Nerve. (D) EGFP+/p75+ cells are absent in the DRG and present in Sciatic Nerve. Immunohistochemistry in neurofibromas after adult tamoxifen exposure within the PlpCre;Nf1fl/fl model shows EGFP double labeling with S100β+ (B), p75 (D) but not GFAP+ (C).